Navigation Links
AcelRx Pharmaceuticals to Hold Third Quarter 2013 Financial Results Conference Call and Webcast on November 5, 2013
Date:10/22/2013

REDWOOD CITY, Calif., Oct. 22, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release third quarter 2013 financial results after market close on Tuesday, November 5, 2013.  AcelRx management will host an investment-community conference call at 4:30 p.m. eastern time (1:30 p.m. pacific time) on November 5, 2013 to discuss the financial results and provide a corporate update.

Investors who wish to participate in the conference call may do so by dialing (877) 870-4263 for domestic callers, (855) 669-9657 for Canadian callers or (412) 317-0790 for international callers. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the company's website at www.acelrx.com and clicking on the webcast link on the Investors home page.

A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of the company's website at www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso™, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps.  AcelRx has announced positive results from each of the three Phase 3 clinical trials completed for Zalviso, and has submitted an NDA to the FDA seeking approval for Zalviso to be used to treat moderate-to-severe acute pain in the hospital setting.  AcelRx has also announced positive top-line results for a Phase 2 trial for ARX-04, a product candidate for the treatment of moderate-to-severe acute pain in a medically supervised setting, funded through a grant from the U.S. Army Medical Research and Materiel Command.  The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.  For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the Phase 3 clinical trial data for Zalviso and the therapeutic potential of Zalviso and AcelRx Pharmaceuticals' other product candidates. These forward-looking statements are based on AcelRx's current expectations and inherently involve significant risks and uncertainties.  AcelRx's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the fact that FDA may not accept for filing the Zalviso NDA; AcelRx's ability to receive regulatory approval for Zalviso, including whether the results of the Phase 3 clinical trials for Zalviso are sufficient to obtain marketing approval for Zalviso, which depends on the ability of AcelRx to demonstrate to the satisfaction of the FDA the safety and efficacy of Zalviso based upon its findings of the Phase 3 trials; any delays or inability to obtain and maintain regulatory approval of its product candidates, including Zalviso, in the United States and Europe; its ability to attract funding partners or collaborators with development, regulatory and commercialization expertise; its ability to obtain sufficient financing to commercialize Zalviso;  the market potential for its product candidates; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx's  U.S. Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q filed with the SEC on August 12, 2013.  AcelRx undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

(Logo: http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
2. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
3. AcelRx Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on July 12th
4. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
5. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
6. AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012
7. AcelRx Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Healthcare Conference
8. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
9. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
10. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
11. AcelRx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... YORK , April 28, 2016  While ... notably complement the company,s valve repair and stent ... move also places Abbott more firmly into patient ... of the fastest growing device areas, with double-digit ... its recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... 28, 2016  Marking its one year anniversary ... ovarian cancer risk test, Color Genomics ... that highly impact the most common hereditary cancers ... Color Test analyzes hereditary cancer risks for breast, ... cancers. The Color Test is physician ordered and ...
(Date:4/28/2016)... , April 28, 2016  The blood testing ... million dollars, according to Kalorama Information and The Freedonia ... immunoassays and nucleic acid testing.  The healthcare research firm ... progress in developing blood collection stations and in improving ... in Kalorama Information,s report, Blood Testing Market ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 29, 2016 , ... Memorial Healthcare System Graduate Medical ... (ACGME) that it has received accreditation for its residency program on Physical Medicine ... that Memorial is currently pursuing, including Pediatrics and Internal Medicine. This accreditation allows ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members ... celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural Health Care ... Cumming), offers a 70% tax credit to individuals and corporations which donate directly to ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White ... repaying their loans, more information about their loan terms and accounts, and more ... loan debt, including federal and private loans, has reached $1.3 trillion, with 43 ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... infants born with severe congenital diaphragmatic hernia have better survival rates if surgery ... diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
Breaking Medicine News(10 mins):